| Description | Picumast shows antiallergic activity and can be utilized in the treatment of asthma. Picumast may be used in the treatment of therapeutic allergic airway diseases. |
| In vivo | Picumast dihydrochloride（2.5 mg；aerosol；过敏性羊；n = 7）对早期和晚期气道反应分别提供了48%和55%的保护效果（均p<0.05）。Picumast dihydrochloride（5 mg；aerosol；过敏性羊；n = 7）对早期反应提供了63%的保护效果，对晚期反应提供了81%的保护效果。[1] |
| molecular weight | 440.96 |
| Molecular formula | C25H29ClN2O3 |
| CAS | 39577-19-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 1 mg/mL, Sonication is recommended. |
| References | 1. Abraham WM. Effect of picumast dihydrochloride on antigen-induced early and late airway responses in allergic sheep. Arzneimittelforschung. 1989;39(10A):1328-1331. 2. Wittenbrink-Dix AM, et al. Study of potential kinetic interactions of picumast dihydrochloride and theophylline in vitro and after oral administration in man. Arzneimittelforschung. 1989;39(10A):1339-1343. 3. Roesch A, et al. Antiallergic activity of picumast dihydrochloride in several animal species. Arzneimittelforschung. 1989;39(10A):1310-1316. 4. Besenfelder E, et al. Metabolism of picumast after administration of picumast dihydrochloride and antiallergic activity of the main metabolites. Arzneimittelforschung. 1989;39(10A):1317-1320. 5. Franke W, et al. Double-blind multicenter controlled clinical study comparing the efficacy of picumast dihydrochloride versus astemizole and placebo in patients with seasonal allergic rhinitis. Arzneimittelforschung. 1989;39(10A):1360-1363. |